

NEW DRUGS

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

中国新药杂志
二〇二一年
第三十卷
第四期
第289-384页
半月刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6

中國新葯雜誌



4

2021

Vol.30 | No.4

日本药品专利期限补偿制度对中国新药研发的启示
调脂药物的药学特点及生产现场检查的常见问题讨论
药物神经毒性非临床安全性评价方法和技术概述
人胚胎干细胞诱导分化的肝样细胞质量评价研究
奥贝胆酸对2型糖尿病KKAy小鼠的糖脂稳态影响

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



万方数据

•新药述评与论坛•

- 289 日本药品专利期限补偿制度对中国新药研发的启示·····顾东蕾, 潘晓梅, 杨静
295 浅谈欧洲药品专利期补偿制度的现状和发展趋势·····刘晴, 黄超峰

•新药注册与审评技术•

- 300 调脂药物的药学特点及生产现场检查的常见问题讨论·····刘孟斯, 宋丹, 刘瑾欣

•重大新药创制专项巡礼•

- 306 药物神经毒性非临床安全性评价方法和技术概述·····田康, 屈哲, 吕建军, 等
312 基于临床试验机构办公室质量控制认知的调研·····肖爽, 王彦, 朱雪琦, 等

•生物医药前沿•

- 320 人胚胎干细胞诱导分化的肝样细胞质量评价研究·····纳涛, 孙懿, 吴婷婷, 等

•综述•

- 333 以蛋白质为载体的纳米制剂质量研究进展·····张金霞, 李楠, 李晓琴, 等
339 免疫分析法用于中药活性成分检测和质量控制研究进展·····朱瑞萱, 张淼, 王朋倩, 等
347 杜仲多糖的提取方法及药理作用研究进展·····张晓芳, 胡文忠, 姜爱丽, 等

•实验研究•

- 352 奥贝胆酸对2型糖尿病KKAy小鼠的糖脂稳态影响·····曹慧, 环奕, 李彩娜, 等
357 ¹H定量核磁共振波谱法测定盐酸莫西沙星及其杂质7-氨基莫西沙星喹啉羧酸的含量·····冯玉飞, 吴先富, 肖新月
362 参茸宁心颗粒的薄层鉴别及含量测定研究·····段秀俊, 刘培, 叶花, 等

•药物安全与合理应用•

- 369 托珠单抗致不良反应文献分析·····舒冰, 蒋威, 沈爱宗
377 嵌合抗原受体T细胞免疫疗法治疗2种血液恶性肿瘤药物经济学的系统评价·····代展菁, 常峰, 黄严琴, 等

- 289 Inspiration of the extension of duration of patent right in Japan to new drug research and development in China
GU Dong-lei, PAN Xiao-mei, YANG Jing
- 295 Research on European Supplementary protection certificate and development tendency thereof
LIU Qing, HUANG Chao-feng
- 300 Discussion on pharmaceutical characteristics and common problems in manufacturing site inspection of lipid-altering drugs
LIU Meng-si, SONG Dan, LIU Jin-xin
- 306 Overview of nonclinical safety evaluation methods and techniques for drug-induced neurotoxicity
TIAN Kang, QU Zhe, LÜ Jian-jun, *et al*
- 312 A survey on cognition about quality control of clinical trial institutions
XIAO Shuang, WANG Yan, ZHU Xue-qi, *et al*
- 320 A discussion on the quality evaluation practice of human embryonic stem cells-derived hepatocyte-like cells
NA Tao, SUN Yi, WU Ting-ting, *et al*
- 333 Research advance in quality control of protein-based nano-preparations
ZHANG Jin-xia, LI Nan, LI Xiao-qin, *et al*
- 339 Research progress in detection of active ingredients in traditional Chinese medicine based on immunoassay
ZHU Rui-xuan, ZHANG Miao, WANG Peng-qian, *et al*
- 347 Research Progress on Extraction Methods and Pharmacological Effects of *Eucommia ulmoides* Polysaccharide
ZHANG Xiao-fang, HU Wen-zhong, JIANG Ai-li, *et al*
- 352 Effect of obeticholic acid on glycolipid homeostasis in type 2 diabetic KKAY mice
CAO Hui, HUAN Yi, LI Cai-na, *et al*
- 357 Determination of moxifloxacin hydrochloride and its impurity 7-amino-1-cyclopropyl-6-fluoro-1, 4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid by ¹H qNMR
FENG Yu-fei, WU Xian-fu, XIAO Xin-yue
- 362 Research on TLC identification and content determination of Shencao Ningxin Granules
DUAN Xiu-jun, LIU Pei, YE Hua, *et al*
- 369 Literature analysis of adverse drug reactions induced by tocilizumab
SHU Bing, JIANG Wei, SHEN Ai-zong
- 377 Pharmacoeconomic evaluation of CAR-T therapy for two hematological malignancies: a systematic review
DAI Zhan-jing, CHANG Feng, HUANG Yan-qin, *et al*

Directed by: National Medical Products Administration
Sponsored by: China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association
Editor-in-Chief: SANG Guo-wei
Board Chairman: SHI Sheng-yi
Edited by: Editorial Board of Chinese Journal of New Drugs
Published by: Chinese Journal of New Drugs Co., Ltd.
Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China
Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>
E-mail: bianjibu@newdrug.cn
Printer: Beijing Kexin Printing Co., Ltd.
Domestic Distribution: Beijing Post Offices
Overseas Distribution: China International Book Trading Corp.
(P.O.Box 399 Beijing, China)
Domestic Subscription: Local Post Offices
Periodical Registration: ISSN 1003-3734 CN 11-2850/R
Publication Date: February 28, 2021
Copyright: 2021 by Chinese Journal of New Drugs Co., Ltd.

- [16] LIN JK, MUFFLY LS, SPINNER MA, *et al.* Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma[J]. *J Clin Oncol*, 2019, 37(24): 2105 – 2119.
- [17] Institute for Clinical and Economic Review. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value: final evidence report[EB/OL]. (2018) [2020 – 04]. https://icer-review.org/wp-content/uploads/2017/07/ICER_CAR_T_Final_Evidence_Report_032318.pdf.
- [18] WEINSTEIN MC. Recent developments in decision-analytic modelling for economic evaluation[J]. *Pharmacoeconomics*, 2006, 24(11): 1043 – 1053.
- [19] NEUMANN PJ, COHEN JT, WEINSTEIN MC. Updating cost-effectiveness: the curious resilience of the \$50,000-per-QALY threshold[J]. *N Engl J Med*, 2014, 371(9): 796 – 797.
- [20] PRASAD V, MAILANKODY S. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses[J]. *Blood*, 2015, 126(15): 1860 – 1861.
- [21] DAVIES C, BRIGGS A, LORGELLY P, *et al.* The “hazards” of extrapolating survival curves[J]. *Med Decis Making*, 2013, 33(3): 369 – 380.
- [22] DE RIJKSOVERHEID, VOOR NEDERLAND. Rapporten van of voor het ministerie van Volksgezondheid, Welzijn en Sport 2019 [EB/OL]. (2019) [2020 – 05]. <https://www.rijksoverheid.nl/documenten/rapporten/2019/03/11/rapporten-van-of-voor-het-ministerie-van-vws-2019>.
- [23] CADTH OPTIMAL USE REPORT. Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large B-cell lymphoma: clinical report[EB/OL]. (2019) [2020 – 05]. https://cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-clinical-report_jan_2019.pdf.
- [24] CMS. Trump administration makes car t-cell cancer therapy available to medicare beneficiaries nationwide [EB/OL]. (2019) [2020 – 05]. <https://www.cms.gov/newsroom/press-releases/trump-administration-makes-car-t-cell-cancer-therapy-available-medicare-beneficiaries-nationwide>.
- [25] 《中国药物经济学评价指南》课题组刘国恩, 胡善联, 吴久鸿. 中国药物经济学评价指南(2011版)[J]. *中国药物经济学*, 2011, 6(3): 6 – 9, 11 – 48.
- [26] HIGGINS J, JAMES TG. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019) [EB/OL]. 2019[2020 – 10]. <https://training.cochrane.org/handbook/archive/v6>.

编辑:刘卓越/接受日期:2020 – 10 – 20